

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6454397

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
FORMULATION TECHNOLOGIES, LLC DBA PHARMAFORM	07/17/2008
RECEIVING PARTY DATA	
Name:	HIGHLAND THERAPEUTICS INC.
Street Address:	72 SAULTER STREET
City:	TORONTO, ONTARIO
State/Country:	CANADA
Postal Code:	M4M 2H7
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17124102
CORRESPONDENCE DATA	
Fax Number:	(512)322-8388
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	512-322-2500
Email:	crystle.garbade@bakerbotts.com
Correspondent Name:	BAKER BOTTS L.L.P.
Address Line 1:	98 SAN JACINTO BLVD
Address Line 2:	SUITE 1500
Address Line 4:	AUSTIN, TEXAS 78701
ATTORNEY DOCKET NUMBER:	084165.0186
NAME OF SUBMITTER:	CRYSTLE GARBADE
SIGNATURE:	/Crystle Garbade/
DATE SIGNED:	12/16/2020
Total Attachments: 6	
source=Assignment-Formulation-Highland#page1.tif	
source=Assignment-Formulation-Highland#page2.tif	
source=Assignment-Formulation-Highland#page3.tif	
source=Assignment-Formulation-Highland#page4.tif	
source=Assignment-Formulation-Highland#page5.tif	



MASTER DEVELOPMENT AGREEMENT

BY AND BETWEEN

HIGHLAND THERAPEUTICS INC.

AND

FORMULATION TECHNOLOGIES L.L.C.

d/b/a PharmaForm

DATED AS OF

July 17, 2008

TABLE OF CONTENTS

ARTICLE 1	DEFINITIONS	4
ARTICLE 2	SERVICES	9
2.1	Development Program	9
2.2	Regulatory Filings and Meetings	9
2.3	Drug Substance and Safety Information	9
2.4	Timeline	9
2.5	Procurement of Materials	10
2.6	Reports	10
2.7	Patents	10
2.8	Intellectual Property Used in Performance of the Services	12
ARTICLE 3	PAYMENT OBLIGATIONS	12
3.1	Development Payment Schedule and Related Costs	12
3.2	Patent Payments	13
3.3	Clinical Supplies	13
ARTICLE 4	PHARMAFORM INTELLECTUAL PROPERTY DISCLOSURE	14
4.1	PharmaForm Disclosure	14
4.2	Acknowledgment	14
ARTICLE 5	INTELLECTUAL PROPERTY	14
5.1	Ownership and Assignment of Intellectual Property	14
5.2	Liability for Certain Decisions	15
5.3	Licenses	15
ARTICLE 6	CONFIDENTIALITY	16
6.1	Limitations on Disclosure and Use	16
6.2	Exception	16
6.3	Cooperation	17
6.4	Ownership	17
6.5	Trademarks and Trade Names	17
6.6	Remedies	17
6.7	Other Confidentiality Agreements	18
ARTICLE 7	NON-SOLICITATION	18
ARTICLE 8	PUBLICATION	18
8.1	Scientific Publications	18
8.2	Further Restrictions	19
ARTICLE 9	REGULATORY COMPLIANCE	19



ARTICLE 10	REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION	19
10.1	Representations and Warranties.....	19
10.2	Indemnification Covenants	20
10.3	Duty to Indemnify	22
10.4	Limitation of Liability.....	22
ARTICLE 11	TERM AND TERMINATION.....	23
11.1	Term of Agreement.....	23
11.2	Termination of Agreement.....	23
ARTICLE 12	MISCELLANEOUS	25
12.1	Remedies For Breach of Restrictive Covenants	25
12.2	Complete Agreement	25
12.3	Notice	25
12.4	Independent Contractor.....	26
12.5	Assignment.....	26
12.6	Force Majeure	27
12.7	No Waiver	27
12.8	Severability	27
12.9	Governing Law and Venue	28
12.10	Binding Agreement.....	28
12.11	No Third Party Beneficiaries	28
12.12	Survival	28
12.13	Headings; Interpretation.....	28
12.14	Amendment.....	28
12.15	Counterparts	28



MASTER DEVELOPMENT AGREEMENT

This Master Development Agreement (this "Agreement") is made by and between Formulation Technologies L.L.C., a Texas limited liability company ("PharmaForm"), having a place of business at 11400 Burnet Road, Suite 4010, Austin, Texas 78758 and Highland Therapeutics Inc., a corporation having a place of business at 72 Sautter Street, Toronto, Ontario, Canada M4M 2H7 ("Client").

RECITALS

A. PharmaForm is in the business of pharmaceutical drug product research, development, characterization, manufacturing and commercialization, for itself, its Affiliates and Third Parties.

B. Client is in the business of developing pharmaceutical products for the treatment of ADHD.

C. Client desires to engage PharmaForm and PharmaForm desires to be engaged to provide the Services (defined below), all in accordance with the terms and conditions set forth in this Agreement and the attached R&D Plan.

AGREEMENT

For good and valuable consideration, including the mutual covenants herein contained, the parties hereto hereby agree as follows:

ARTICLE 1.

DEFINITIONS

"Affiliate" means, as to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common

ARTICLE 5.


INTELLECTUAL PROPERTY.

5.1 Ownership and Assignment of Intellectual Property. Client shall be the sole owner of all Results, and PharmaForm hereby irrevocably, immediately and exclusively assigns and, to the extent any such assignment cannot be made at present, agrees promptly to assign all its right, title and interest in and to any and all Results to Client. PharmaForm shall ensure that all its employees and agents performing any or all of the Services are obligated under a binding written agreement to assign in full to PharmaForm all Results. PharmaForm shall keep and maintain full and accurate records concerning all work performed in connection with the Services.




IN WITNESS WHEREOF, the parties have executed this Agreement to be effective as of the 17 day of July, 2008 (the "Effective Date").

PHARMAFORM:


By: Michael M. Crowley, Ph.D.
Its: Vice President, Business Development

CLIENT:


By: David Lickrish
Its: Chairman and Chief Executive Officer

11400 Barnes Road
Building 4, Suite 4010
Austin, Texas 78758
DOCSTOR: 14962472

Confidential
Page 29 of 30

Ph (512) 834-0449
Fax (512) 834-2103
www.pharmaform.com